Elevation Oncology Inc

Elevation Oncology Inc ELEV

Dividend Summary



There have not been any declared dividends recently.

Latest Dividends
Summary Previous dividend Next dividend
Status
Type
Per share
Declaration date
Ex-div date
Pay date

Enter the number of Elevation Oncology Inc shares you hold and we'll calculate your dividend payments:

Previous Payment
Next Payment
Forecast Accuracy
We have not made any dividend predictions for Elevation Oncology Inc
Dividend Yield Today
0.0%
The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price
The table below shows the full dividend history for Elevation Oncology Inc
Status Type Decl. date Ex-div date Pay date Decl. Currency Forecast amount Decl. amount Accuracy
There are no Elevation Oncology Inc dividends.
Year Amount Change
2006 0.0c
2007 0.0c
0%
2008 0.0c
0%
2009 0.0c
0%
2010 0.0c
0%
2011 0.0c
0%
2012 0.0c
0%
2013 0.0c
0%
2014 0.0c
0%
2015 0.0c
0%
2016 0.0c
0%
2017 0.0c
0%
2018 0.0c
0%
2019 0.0c
0%
2020 0.0c
0%
2021 0.0c
0%
2022 Sign Up Required

Elevation Oncology Inc Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.
Dividend Yield Today
0.0%
Optimized Yield
Sign Up Required
52 Week High
0.0% on 04 January 2022
52 Week Low
0.0% on 04 January 2022
Next Ex-Div-Date Countdown
Sign Up Required

About Elevation Oncology Inc

Elevation Oncology, Inc is a clinical stage biopharmaceutical company. The Company is focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. It is focuses on identifying oncogenic drivers with other driver alterations and in the conduct of clinical trials. The Company’s lead program is focused on neuregulin-1 (NRG1), fusions, which are genomic alterations that are identified as oncogenic driver alterations. Its NRG1 is the primary activating ligand of HER3. The Company's clinical trial, CRESTONE, is a Phase II study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion.

Sector
Pharmaceuticals & Biotechnology
Country
United States
Share Price
$0.92 (yesterday's closing price)
Shares in Issue
23 million
Market Cap
$21mn
CADI
The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends
0
Market Indices
none
No articles found